Literature DB >> 27121394

Assessing blood platelets as RNA biomarker source for prostate cancer.

Jörg Hänze1, Peter Jakubowski1, Hendrik Heers1, Axel Hegele1, Nina Timmesfeld2, Rainer Hofmann1, Peter J Olbert1.   

Abstract

CONTEXT: Blood platelets may offer as RNA biomarker source for cancer as recently described for an oncogenic transcript in glioma patients and for PCA3 in prostate cancer (PCa) patients.
OBJECTIVE: Here, we elaborated on this aspect for PCa.
MATERIALS AND METHODS: PCA3 and other PCa-associated RNA markers were measured in platelets of PCa patients (cases) and healthy subjects (controls) in comparison to PCa cell lines by relative quantitative RT-PCR.
RESULTS: The RNA markers displayed heterogeneous expression patterns in cell lines and platelets, however, without significant differences between cases and controls. DISCUSSION AND
CONCLUSION: The data do not support platelets as a profitable RNA source for early detection of PCa. Nonetheless, certain PCa-derived RNA markers in platelets may merit further investigation as potential prognostic biomarkers for PCa.

Entities:  

Keywords:  Biomaterial; PCA3; thrombocyte

Mesh:

Substances:

Year:  2016        PMID: 27121394     DOI: 10.3109/1354750X.2016.1171909

Source DB:  PubMed          Journal:  Biomarkers        ISSN: 1354-750X            Impact factor:   2.658


  2 in total

1.  Prostate specific membrane antigen (PSMA) in urothelial cell carcinoma (UCC) is associated with tumor grading and staging.

Authors:  Henner Schreiber; Jörg Hänze; Wilhelm Nimphius; Frederik Anton Verburg; Markus Luster; Rainer Hofmann; Axel Hegele
Journal:  J Cancer Res Clin Oncol       Date:  2020-01-02       Impact factor: 4.553

Review 2.  Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies.

Authors:  Yongping Zhou; Sijin Cheng; Abdel Hamid Fathy; Haixin Qian; Yongzhao Zhao
Journal:  Onco Targets Ther       Date:  2018-04-05       Impact factor: 4.147

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.